Longitudinal assessment of lung function in Swiss childhood cancer survivors

Rahel Kasteler; Maria Otth; Florian S Halbeisen; Luzius Mader; Florian Singer; Jochen Rössler; Nicolas X von der Weid; Marc Ansari; Claudia E Kuehni

doi:10.1101/2022.03.16.22272460

Abstract

Rationale Childhood cancer survivors (CCSs) are at increased risk for pulmonary morbidity due to exposure to lung-toxic treatments, including specific chemotherapies, radiotherapy, and surgery. Longitudinal data on lung function, with information on how outcomes change over time, in CCSs are scarce.

Objectives To investigate lung function trajectories in childhood cancer survivors over time and investigate the association with lung-toxic treatment.

Methods This retrospective, multi-center cohort study included CCSs, who were diagnosed between 1990 and 2013 in Switzerland and had been exposed to lung-toxic chemotherapeutics or thoracic radiotherapy. Pulmonary function tests (PFTs) were obtained from hospital charts. We assessed quality of PFTs systematically and calculated z-scores and percentage predicted of forced expiratory volume in first second (FEV1), forced vital capacity (FVC), FEV1/FVC ratio, total lung capacity (TLC) and diffusion capacity for carbon-monoxide (DLCO) based on recommended reference equations. We described lung function over time and determined risk factors for change in FEV1 and FVC using multivariable linear regression.

Results We included 790 PFTs from 183 CCSs, with a median age of 12 years (IQR 7 – 14) at diagnosis. Common diagnoses were lymphoma (55%), leukemia (11%) and CNS tumors (12%). Median follow-up time was 5.5 years. Half (49%) of CCSs had at least one abnormal pulmonary function parameter, with restrictive impairment being common (22%). Trajectories of FEV1 and FVC started at z-scores of -1.5 at diagnosis and remained low throughout follow-up. CCSs treated with thoracic surgery started particularly low, with an FEV1 of -1.08 z-scores (−2.02 to -0.15) and an FVC of -1.42 z-scores (−2.27 to -0.57) compared to those without surgery. In CCS exposed to lung-toxic chemotherapeutics FEV1 z-scores increased slightly over time (0.12 per year; 95%CI 0.02 - 0.21).

Conclusion The large proportion of CCSs with reduced lung function identified in this study underlines the need for more research and long-term surveillance of this vulnerable population.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was funded by Swiss Cancer Research (grant no: KFS-4157-02-2017, KLS/KFS-4825-01-2019 and KFS-5302-02-2021), Kinderkrebshilfe Schweiz and Lung League Bern. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. FS reports personal fees from Vertex, personal fees from Novartis, grants from the Swiss Society of Cystic Fibrosis (CFCH), Lungenliga Bern, outside the submitted work.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Ethics Committee of the Canton of Bern Switzerland gave ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

All authors have revised earlier drafts and approved the final article.
Source of funding This study was supported by Swiss Cancer Research (grant no: KFS-4157-02-2017, KLS/KFS-4825-01-2019 and KFS-5302-02-2021), Kinderkrebshilfe Schweiz and Lung League Bern. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
FS reports personal fees from Vertex, personal fees from Novartis, grants from the Swiss Society of Cystic Fibrosis (CFCH), Lungenliga Bern, outside the submitted work.